Hussein Ali El-Khechen

Hussein Ali El-Khechen

Auto-generated profile, based on publicly available information

Hussein Ali El-Khechen

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in Pilot and Feasibility Studies
Verified
Journal Article
Open access
PDF file
MKMohammed I. U. Khan
Mohammed I. U. Khan
HBHartirath K. Brar
Hartirath K. Brar
CSCynthia Y. Sun
Cynthia Y. Sun
RHRebecca He
Rebecca He
HEHussein A. El-Khechen
Hussein A. El-Khechen
CQCarlos Quiñonez
Carlos Quiñonez
Background: Pilot and feasibility studies (PAFS) are smaller investigations seeking to assess the feasibility of conducting a larger more definitive study. In late 2016, the CONSORT statement was extended to disseminate good practices for reporting of randomized pilot and feasibility trials. In this quality assurance review, we assessed whether PAFS in the top dental speciality journals adhere to good practices of conduct and reporting, by prioritizing assessment of feasibility and stating pre-defined progression criteria to inform the decision to pursue funding for a larger trial. Methods: With the help of a librarian, we searched MEDLINE and EMBASE from 2017 to 2020, inclusive, for PAFS in the top 3 journals from each of the 10 dental specialties. We collected data on methodological and general characteristics of the studies, their objectives, and reporting of items recommended in the CONSORT extension. Results: Of the 111 trials included, 51.4% (95% CI 41.7–61.0%) stated some indication of intent to assess feasibility while zero reported progression criteria; 74.8% (95% CI 65.6–82.5%) of trials used the terms “pilot” or “feasibility” in their titles and 82.9% (95% CI 74.6–89.4%) of studies stated there is a need for a future trial, but only 9.0% (95% CI 4.4–15.9%) stated intent to proceed to one. Most of the studies, 53.2% (95% CI 43.4–62.7%), reported hypothesis testing without cautioning readers on the generalizability of the results. Studies that used the terms “pilot” or “feasibility” in their title were less likely to have feasibility objectives, compared to trials that did not, with an odds ratio (OR) of 0.310 (95% CI 0.103–0.930; p = 0.037). Compared to trials that did not conduct hypothesis testing, trials that conducted hypothesis testing were significantly less likely to assess feasibility, among them, trials that cautioned readers on the generalizability of their results had an OR of 0.038 (95% CI 0.005–0.264; p < 0.001) and trials that did not caution readers on the generalizability of their results had an OR of 0.043 (95% CI 0.008–0.238; p = 0.001). Conclusion: Many PAFS in dentistry are not conducted with the intent of assessing feasibility, nor do they state progression criteria, and few report intent to proceed to a future trial. Misconceptions about PAFS can lead to them being poorly conducted and reported, which has economic and ethical implications. Research ethics boards, funding agencies, and journals need to raise their standards for the conduct and reporting of PAFS, and resources should be developed to address misconceptions and help guide researchers on the best practices for their conduct and reporting.

30 November 2021 in Pilot and Feasibility Studies
Verified
Journal Article
Open access
PDF file
HEHussein Ali El-Khechen
Hussein Ali El-Khechen
MKMohammed Inam Ullah Khan
Mohammed Inam Ullah Khan
SLSelvin Leenus
Selvin Leenus
OOOluwatobi Olaiya
Oluwatobi Olaiya
ZDZoha Durrani
Zoha Durrani
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
Background: Pilot studies are essential in determining if a larger study is feasible. This is especially true when targeting populations that experience stigma and may be difficult to include in research, such as people with HIV. We sought to describe how pilot studies have been used to inform HIV clinical trials.Methods: We conducted a methodological study of pilot studies of interventions in people living with HIV published until November 25, 2020, using Medline, Embase, and Cochrane Controlled Register of Trials (CENTRAL). We extracted data on their nomenclature, primary objective, use of progression criteria, sample size, use of qualitative methods, and other contextual information (region, income, level, type of intervention, study design).Results: Our search retrieved 10,597 studies, of which 248 were eligible. The number of pilot studies increased steadily over time. We found that 179 studies (72.2%) used the terms “pilot” or “feasibility” in their title, 65.3% tested feasibility as a primary objective, only 2% used progression criteria, 23.9% provided a sample size estimation and only 30.2% used qualitative methods.Conclusions: Pilot studies are increasingly being used to inform HIV research. However, the titles and objectives are not always consistent with piloting. The design and reporting of pilot studies in HIV could be improved.

11 August 2022 in JMIR Data
Verified
Journal Article
Open access
LMLawrence Mbuagbaw
Lawrence Mbuagbaw
DJDiya Jhuti
Diya Jhuti
GZGohar Zakaryan
Gohar Zakaryan
HEHussein El-Kechen
Hussein El-Kechen
NRNadia Rehman
Nadia Rehman
OMOluwatoni Makanjuola
Oluwatoni Makanjuola
Background: The Joint United Nations Programme on HIV/AIDS has set targets for 2025 regarding people living with HIV. For these targets to be met, 95% of people with HIV would need to know their HIV status, 95% of people with HIV would need to be receiving antiretroviral therapy, and 95% of people on antiretroviral therapy would need to be virally suppressed. Some countries are on track to meet these targets. However, within and across countries, several vulnerable populations may not meet these targets. This is in part because several approaches to improving the cascade of care after an HIV diagnosis are not tailored to and are not appropriate for vulnerable populations, such as men who have sex with men, sex workers, people who inject drugs, Black people, people in prisons, women, and youth. To inform research, policy, and practice, there is a need for curated data on HIV care cascade research. Objective: The CASCADE database is a repository of randomized clinical HIV trials. It was designed to inform, support, and improve HIV care cascade research, systematic reviews, and evidence maps. Methods: PubMed, Embase, CINAHL, PsycINFO, Web of Science, and the Cochrane Library were searched to obtain randomized trials that were designed to address at least one of the following care cascade outcomes: the initiation of therapy, adherence to medication, retention in care, and engagement in care. Data were screened and extracted in duplicate using DistillerSR software (Evidence Partners Incorporated) and were cataloged based on the following features: year, income level, setting, the delivery of the intervention, the population receiving the intervention, intervention type, and the level of pragmatism of the intervention. Results: A total of 298 HIV clinical trials are included in the CASCADE database, of which 162 (54.4%) were conducted in high-income countries, and 116 (38.9%) targeted vulnerable populations. Adherence to antiretroviral therapy was the most investigated HIV care cascade outcome (216/298, 72.5%), followed by retention in care (34/298, 11.4%). CASCADE has a user-friendly interface with simple and advanced search features. The CASCADE database has inspired 2 methodological papers and 13,567 website visits from over 10 countries. Conclusions: CASCADE is the first database dedicated to trials that focus on the HIV care cascade, and it can be used for systematic reviews, evidence maps, and methodological research. It is freely accessible, and the data can be downloaded in CSV format.

16 March 2022 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
PDF file
RMRosa Stalteri Mastrangelo
Rosa Stalteri Mastrangelo
AHAnisa Hajizadeh
Anisa Hajizadeh
TPThomas Piggott
Thomas Piggott
MLMark Loeb
Mark Loeb
MWMichael Wilson
Michael Wilson
RNRobby Nieuwlaat
Robby Nieuwlaat
Hospitals continue to face challenges in reducing incorrect antibiotic use due to social and cultural factors at the level of the health system, the care facility, the provider, and the patient. The objective of this paper is to highlight the social and cultural drivers of antimicrobial use and resistance and targeted interventions for secondary and tertiary care settings in Canada and other OECD countries. This paper is an extension of the synthesis conducted for the Public Health Agency of Canada’s 2019 Spotlight Report: Preserving Antibiotics Now and Into the Future. We conducted a systematic review with a few modifications to meet rapid timelines. We conducted a search in Ovid MEDLINE and McMaster University’s evidence databases for systematic reviews and then for individual Canadian studies. To cast a wider net, we searched OECD organization websites and screened reference lists from systematic reviews. We synthesized the evidence narratively and categorized the evidence into macro-, meso-, and microlevel. A total of 70 studies were (a) from OCED countries and summarized evidence of potential sociocultural antimicrobial resistance and use barriers or facilitators and/or interventions addressing these challenges; (b) systematic reviews with 50% of included studies that are situated in secondary and tertiary settings; and (c) published in Canada’s two official languages, English and French. We found that hospital structures and policies may influence antibiotic utilization and variations in antimicrobial management. Microlevel factors may sway inappropriate prescribing among clinicians. The amount and type of antibiotics used may affect resistance rates. Interventions were mainly comprised of antibiotic stewardship and training that modify clinician behavior and that educate patients and carers. This evidence synthesis illustrates the various drivers of, and interventions for, antimicrobial use and resistance at the macro-, meso-, and microlevel in secondary and tertiary settings. We demonstrate that upstream drivers may lead to downstream events that influence antimicrobial resistance.